JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS
 QUICK SEARCH:   [advanced]


     


First published online March 14, 2008
J Nucl Med 2008, doi:10.2967/jnumed.107.046227
© 2008 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.107.046227v1
49/4/637    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyagawa, T.
Right arrow Articles by Blasberg, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyagawa, T.
Right arrow Articles by Blasberg, R. G.


Imaging of HSV-tk Reporter Gene Expression: Comparison Between [18F]FEAU, [18F]FFEAU, and Other Imaging Probes

Tadashi Miyagawa 1, George Gogiberidze 1, Inna Serganova 1, Shangde Cai 2, Julius A. Balatoni 3, Howard T. Thaler 4, Lyudmila Ageyeva 1, Nagavarakishore Pillarsetty 5, Ronald D. Finn 6, and Ronald G. Blasberg 7*

1 Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York
2 Radiochemistry/Cyclotron Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York
3 Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York; Radiochemistry/Cyclotron Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York
4 Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
5 Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York; Radiochemistry/Cyclotron Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
6 Radiochemistry/Cyclotron Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York
7 Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York

* To whom correspondence should be addressed. E-mail: Blasberg{at}neuro1.mskcc.org.


   Abstract

Herpes virus type 1 thymidine kinase (HSV1-tk) and the mutant HSV1-sr39tk are the 2 most widely used "reporter genes" for radiotracer-based imaging. Two pyrimidine nucleoside analogs, [18F]FEAU (1-(2'-deoxy-2'-fluoro-{beta}-D-arabinofuranosyl)-5-ethyluridine) and [18F]FFEAU (1-(2'-deoxy-2'-fluoro-{beta}-D-arabinofuranosyl)-5-(2-fluoroethyl)uridine), have generated recent interest as potential new probes for imaging HSV1-tk and HSV1-sr39tk gene expression. Methods: We compared [18F]FEAU and [18F]FFEAU with a series of other pyrimidine nucleoside derivatives (including 1-(2'-deoxy-2'-fluoro-{beta}-D-arabinofuranosyl)-5-iodouridine [FIAU]) and with acycloguanosine analogs using a stable HSV1-tk transduced cell line (RG2TK+) and wild-type RG2 cells. Results: The in vitro accumulation data and the calculated and normalized clearance constant, nKi, as well as sensitivity and selectivity indices indicated that 2 pyrimidine nucleoside probes, [18F]FEAU and [18F]FFEAU, had the best uptake characteristics. These probes were selected for further dynamic PET studies in nude rats bearing subcutaneous RG2TK+ and RG2 tumors. The 2-h postinjection [18F]FEAU uptake levels were 3.3% ± 1.0% and 0.28% ± 0.07% dose/cm3 in subcutaneous RG2TK+ and RG2 tumors, respectively, and 2.3% ± 0.2% and 0.19% ± 0.01% dose/cm3, respectively, for [18F]FFEAU. The corresponding RG2TK+/RG2 uptake ratios were 11.5 ± 1.5 and 12.2 ± 1.4, respectively. The inherent problem of comparing different radiolabeled pyrimidine nucleoside and guanosine-based probes for imaging HSV1-tk expression using different transduced cell lines and assay systems in the absence of an independent thymidine kinase–enzyme assay is discussed. Conclusion: For HSV1-tk reporter systems that require a 1- to 4-h PET paradigm, HSV1-tk-[18F]FEAU is the current top contender.

Key Words: HSV1-tk, herpes simplex virus type 1 thymidine kinase, PET, FEAU, FFEAU, FIAU, 18F, reporter gene




This article has been cited by other articles:


Home page
FASEB J.Home page
I. Serganova, E. Moroz, J. Vider, G. Gogiberidze, M. Moroz, N. Pillarsetty, M. Doubrovin, A. Minn, H. T. Thaler, J. Massague, et al.
Multimodality imaging of TGF{beta} signaling in breast cancer metastases
FASEB J, August 1, 2009; 23(8): 2662 - 2672.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
J. K. Willmann, R. Paulmurugan, M. Rodriguez-Porcel, W. Stein, T. J. Brinton, A. J. Connolly, C. H. Nielsen, A. M. Lutz, J. Lyons, F. Ikeno, et al.
Imaging Gene Expression in Human Mesenchymal Stem Cells: From Small to Large Animals1
Radiology, July 1, 2009; 252(1): 117 - 127.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
J. K. Willmann, R. Paulmurugan, M. Rodriguez-Porcel, W. Stein, T. J. Brinton, A. J. Connolly, C. H. Nielsen, A. M. Lutz, J. Lyons, F. Ikeno, et al.
Imaging Gene Expression in Human Mesenchymal Stem Cells: From Small to Large Animals
Radiology, April 14, 2009; (2009) 2513081616.
[Abstract] [Full Text]


Home page
JNMHome page
B. Zhao, L. H. Schwartz, and S. M. Larson
Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers
J. Nucl. Med., February 1, 2009; 50(2): 239 - 249.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.